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Abstract: The number of elderly patients is increasing worldwide. This will have a significant 
impact on the practice of anesthesia in future decades. Anesthesiologists must provide care for 
an increasing number of elderly patients, who have an elevated risk of perioperative morbidity 
and mortality. Complications related to postoperative residual neuromuscular blockade, such as 
muscle weakness, airway obstruction, hypoxemia, atelectasis, pneumonia, and acute respiratory 
failure, are more frequent in older than in younger patients. Therefore, neuromuscular blockade 
in the elderly should be carefully monitored and completely reversed before awakening patients 
at the end of anesthesia. Acetylcholinesterase inhibitors are traditionally used for reversal of 
neuromuscular blockade. Although the risk of residual neuromuscular blockade is reduced by 
reversal with neostigmine, it continues to complicate the postoperative course. Sugammadex 
represents an innovative approach to reversal of neuromuscular blockade induced by amin-
osteroid neuromuscular-blocking agents, particularly rocuronium, with useful applications in 
clinical practice. However, aging is associated with certain changes in the pharmacokinetics of 
sugammadex, and to date there has been no thorough evaluation of the use of sugammadex in 
elderly patients. The aim of this review was to perform an analysis of the use of sugammadex 
in older adults based on the current literature. Major issues surrounding the physiologic and 
pharmacologic effects of aging in elderly patients and how these may impact the routine use of 
sugammadex in elderly patients are discussed.
Keywords: sugammadex, aging, elderly, neuromuscular blockade, rocuronium, anesthesia, 
safety
Introduction
Between now and 2030, every country will experience population aging, a trend 
that is both pronounced and historically unprecedented. Over the past six decades, 
countries of the world experienced only a slight increase in the proportion of people 
aged 60 years: from 8% to 10%.1 In the next four decades, this group is expected to 
rise to 22% of the total population, an increase from 800 million to 2 billion people.1 
This will have a major impact on the practice of anesthesia in future decades. Approxi-
mately 50% of elderly patients will require anesthesia for a surgical intervention, and 
thus the population of patients presenting for elective surgery will be sicker and at 
greater risk of perioperative complications.2,3
Several factors may contribute to increased postoperative morbidity and mortality 
in elderly persons. Aging results in physiologic changes within all organ systems, with 
changes in the respiratory, cardiovascular, and renal systems being of particular impor-
tance to anesthesia. Furthermore, aging is accompanied by an increased risk of chronic 
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disease, which may further limit organ function and accelerate 
the age-related decrease in reserve capacity of the affected 
organs.4 Drug disposition, metabolism, and excretion may be 
altered in elderly patients as a result of several factors, including 
changes in pharmacokinetics and pharmacodynamics, altera-
tions in receptor sensitivity, and impairment of the body’s nor-
mal homeostatic mechanisms.2 Knowledge of these age-related 
factors will allow anesthesiologists to maximize perioperative 
outcomes, while maintaining safety and efficiency.3
Incomplete recovery from neuromuscular blockade 
(NMB) after anesthesia and surgery continues to be a 
common problem in the postanesthesia care unit (PACU). 
Despite routine use of anticholinesterase reversal agents, 
20%–40% of patients continue to arrive in the PACU with 
objective evidence of residual NMB.5,6 Numerous clinical 
studies have documented that incomplete recovery from 
NMB is associated with a variety of adverse events in the 
early postoperative period, including muscle weakness, 
airway obstruction, hypoxemic episodes, postoperative 
respiratory complications (eg, atelectasis, pneumonia), 
and respiratory failure.5,6 In a prospective, cohort-matched 
observational study, Murphy et al found that the incidence of 
postoperative residual NMB was 57.7% in elderly patients, 
but only 30% in younger patients (difference −27.7%, 99% 
CI −41.2% to −13.1%; P,0.001).7 Muscle weakness, airway 
obstruction, hypoxemic events, postoperative pulmonary 
complications, and increased PACU and hospital lengths of 
stay were observed more frequently in the elderly (P,0.01 
for all).7 In a prospective cohort study of 599 adult patients 
who received NMB agents (NMBAs) during general anes-
thesia, Stewart et al found that adverse respiratory events 
in the PACU were more frequent in patients with residual 
NMB (P=0.033), which was significantly associated with 
age (adjusted relative risk 1.17, 95% CI 1.06–1.29 per 
10-year increase).8 Therefore, the elderly have an increased 
risk of postoperative residual NMB and associated adverse 
outcomes compared with younger adults.7,8
Altered pharmacokinetics of NMBAs in elderly patients 
lead to prolonged duration of action of these drugs and 
delayed recovery from NMB compared to younger subjects. 
Although this mainly applies to aminosteroid NMBAs, ben-
zylisoquinoline NMBAs may also require dose adjustment to 
prevent residual NMB. Therefore, NMB in the elderly should 
be routinely monitored and completely reversed before 
awakening patients at the end of anesthesia.9–12 Differences 
between young and elderly patients with respect to antago-
nism of NMB by acetylcholinesterase inhibitors have been 
reported. Young et al noted prolonged duration of action 
of neostigmine in aged patients (32±10 vs 11±2 minutes, 
P,0.05),13 confirming previous data (42±10 vs 13±14 
minutes in older vs younger patients, P,0.01).14 These 
reflect changes observed with aging, such as a decrease in the 
initial volume of distribution in older compared to younger 
patients (0.1±0.4 vs 0.068±0.018 L/kg, P,0.05), which 
allows a greater concentration of neostigmine to be initially 
available to act at the NM junction.13,14 However, this effect 
is balanced by the prolonged duration of action of NMBAs 
in the elderly, so the risk of residual NMB is not avoided in 
the elderly after administering acetylcholinesterase inhibi-
tors. Although reversal with neostigmine decreases the risk 
of residual NMB, it continues to complicate the postoperative 
course, depending on the patient’s age.7,8
Sugammadex represents an innovative approach to 
reversal of NMB induced by aminosteroid NMBAs, particu-
larly rocuronium, with important implications for clinical 
practice.15,16 In a recent meta-analysis, Carron et al found that 
compared to neostigmine, sugammadex was associated with 
faster reversal of NMB (P,0.0001) and lower risk of post-
operative residual NMB after extubation (OR 0.05, 95% CI 
0.01–0.43; P=0.0068).15 Furthermore, compared to neostig-
mine, sugammadex was associated with significantly lower 
likelihood of global (OR 0.47, 95% CI 0.34–0.66; P,0.0001), 
respiratory (OR 0.36, 95% CI 0.14–0.95; P=0.0386), and car-
diovascular (OR 0.23, 95% CI 0.08–0.61; P=0.0036) adverse 
events, as well as postoperative weakness (OR 0.45, 95% CI 
0.21–0.97; P=0.0409).15 Together, these benefits produce 
faster discharge of patients to the surgical ward after general 
anesthesia with sugammadex compared to neostigmine.16
The aforementioned evidence is derived from studies 
that have often excluded elderly patients. To date, there has 
been no thorough evaluation of the use of sugammadex in 
elderly patients. The aim of this review is to analyze the 
use of sugammadex in this older population based on the 
existing literature.
Physiologic and pharmacologic 
effects of aging
The aging process results in progressive functional decline 
in all major organ systems. Until 60 years of age, both basal 
organ function and physiologic reserve (difference between 
basal and maximal organ function) are well maintained. 
Physiologic reserve subsequently diminishes, with a large 
difference in the rate of age-related decline.17 Age-related 
physiologic changes may affect both the pharmacokinetics 
and pharmacodynamics of drugs commonly used for general 
anesthesia (Table 1).
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Cerebral effects of aging
Brain atrophy occurs with increasing age. Evaluating 201 
healthy adults aged 55 years over 6 years, Enzinger et al found 
that the mean annual brain-volume change was −0.4%±0.29% 
(range −1.47 to 0.32%, women −0.39%±0.26% vs 
men −0.41%±0.31%; P=0.76).18 Furthermore, increased 
age was correlated with an accelerated rate of brain atrophy: 
annual brain-volume change in subjects aged 65–75 years 
was twice as high as that of subjects aged 50–54 years 
(−0.55%±0.29% vs −0.28%±0.23%, P,0.0001). While 
cerebral atrophy increases, cerebral perfusion decreases after 
60 years of age. Using the 15O steady-state inhalation method 
and positron-emission tomography in a group of 34 healthy 
volunteers aged 22–82 years, Leenders et al found that 
regional cerebral blood flow, oxygen utilization, and blood 
volume in “pure” gray- and white-matter regions decreased 
with increasing age by ~0.5% per year.19 These changes lead 
to a decrease in the rate of delivery of most anesthetic agents 
to the nervous system, slower brain uptake, slower blood–
brain equilibration, and slower onset of clinical effects.9,20
Respiratory effects of aging
Age-related deterioration of pulmonary function does not 
produce significant symptoms in unstressed individuals.17 
The main changes in the respiratory system with aging 
include decreased lung elasticity, chest-wall compliance, 
vital capacity, alveolar surface area, and diffusion capac-
ity, as well as increased residual volume, dead space, and 
ventilation–perfusion mismatch.9,17,21 Respiratory responses 
to hypoxia and hypercapnia are markedly diminished in 
older patients.17,20,21 Respiratory muscle strength consistently 
declines with age, further increasing the work of breathing.17 
All of these changes increase the risk of gas-exchange abnor-
malities in the perioperative period and enhance sensitivity 
to the respiratory-depressant effects of anesthetics and opioid 
analgesics. Muscle weakness poses additional risks of the 
development of postoperative respiratory complications 
in elderly patients in the setting of incomplete recovery 
from NMB.9,17,20,21
Cardiovascular effects of aging
Aging also produces alterations in cardiovascular physiol-
ogy, and older patients have an inevitable and progressive 
loss of functional reserve.9,17,20,22 Myocardial stiffness and 
increased arterial stiffness are the main cardiovascular 
changes. They lead to increased systolic and diastolic 
blood pressure, left ventricular hypertrophy, and prolonged 
relaxation of the left ventricle in diastole. Myocardial work 
increases. Fibrosis of the cardiac skeleton, associated with 
calcification at the base of the aortic valve, is also present 
Table 1 Main age-related physiologic changes in the elderly and implications for anesthetic management
Body component Changes Anesthetic implications
Nervous system ↓ white and gray matter in the brain (atrophy)
↓ Cerebral blood flow
↑ Sensitivity to anesthetic drugs (eg, propofol, benzodiazepines, 
inhalational agents, ketamine, opioids)
↓ Delivery and longer onset of clinical effects of anesthetic agents
Respiratory system ↓ Lung function
↓ Respiratory responses to hypoxia and hypercapnia
↓ Respiratory muscle strength
↑ Onset time of inhalational agents
↑ Sensitivity to anesthetic drugs (eg, opioids, benzodiazepines)
↑ Sensitivity to NMBAs
Cardiovascular 
system
↓ Cardiac output ↑ Onset time of anesthetic drugs (eg, propofol, inhalational agents, 
NMBAs, sugammadex)
Liver ↓ Liver function
↓ Hepatic blood flow
↓ Phase 1 metabolism (eg, oxidation, reduction, 
hydrolysis)
↓ Clearance of anesthetic drugs eliminated by the liver 
(eg, aminosteroid NMBAs)
Kidney ↓ Renal function
↓ Glomerular filtration rate
↓ Renal blood flow
↓ Clearance of anesthetic drugs eliminated by the kidney (eg, NMBAs, 
sugammadex)
Muscle ↓ Muscle mass (atrophy)
↓ Muscle blood flow
↓ Delivery of anesthetic drugs (eg, NMBAs, sugammadex)
Plasma proteins ↓ Protein binding (eg, albumin)
↓ Activity (eg, plasma cholinesterases)
↑ Potency of anesthetic drugs (eg, propofol)
↑ Duration for anesthetic drugs (eg, succinylcholine, 
benzylisoquinoline NMBAs)
Body composition ↓ Total body water
↓ Lean body mass
↑ Body fat
↑ Potency of anesthetic drugs (eg, propofol, benzodiazepines, opioids)
↑ Duration for lipophilic anesthetic drugs (eg, benzodiazepines, 
inhaled anesthetics)
Note: Data from these studies.9,12,17–34 
Abbreviation: NMBAs, neuromuscular blocking agents.
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
16
2.
11
0.
99
 o
n 
22
-D
ec
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
16
Carron et al
in older adults.9,17,20,22 Cardiac output at rest is decreased in 
older individuals, and maximal heart rate also decreases with 
aging. In healthy, older individuals, increases in cardiac out-
put are primarily accomplished by increasing end-diastolic 
volume and by increasing stroke volume at a similar ejection 
fraction.17 Intrinsic function of both the sympathetic and 
parasympathetic nervous systems decreases, and reactivity 
of baroreceptors and chemoreceptors also decreases with 
aging, leading to a reduced response to postural changes 
and hypotension, as well as an increase in circulating 
catecholamines.9,17,20,22 These changes set the stage for 
isolated systolic hypertension, diastolic dysfunction, heart 
failure, atrioventricular conduction defects, and aortic-valve 
calcification, all diseases found in the elderly. Together, 
age-related cardiovascular changes lead to decreased car-
diovascular capacity in the elderly, explaining the increased 
cardiodepressant effects of many anesthetic drugs and the 
risk of rhythm changes or dysrhythmias after reversal of 
NMB with neostigmine, often given in association with 
muscarinic receptor-antagonist drugs, such as atropine or 
glycopyrrolate.9,17,20,22
Renal effects of aging
Renal function decreases with age. This is caused by loss of 
renal parenchyma (~10% per decade of increasing age),23 
decreased renal blood flow (10% decline per decade),24 and 
decreased glomerular filtration rate (0.4–1.02 mL/min per 
year), all of which contribute to a 30%–50% decrease in 
creatinine clearance between the ages of 20 and 90 years.25 
Despite this decline in renal function, serum creatinine 
levels remain within the normal range, because of reduced 
production of creatinine, a product of muscle catabolism. 
Loss of muscle mass occurs at a rate similar to the rate of 
decrease in glomerular filtration rate.17,20 As a consequence, 
drugs (or metabolites), also including anesthetics and muscle 
relaxants, that are primarily eliminated via the renal system 
have longer half-lives and reach higher peak levels, possibly 
leading to toxicity.9,17
Hepatic effects of aging
Liver mass decreases by 20%–40% during the typical human 
life span,26 with a concomitant decline in hepatic blood flow of 
10% per decade27 and a moderate decline in phase I metabo-
lism of certain drugs.26 Phase I reactions largely depend on the 
action of cytochrome P450 enzymes, which modify drugs by 
oxidation, reduction, or hydrolysis to form metabolites.9,17,26 
Phase II reactions are involved in the subsequent elimination 
of these metabolites by attaching small polar endogenous 
molecules (acetyl, methyl, sulfur, or glucuronide groups) to 
form water-soluble compounds. This process, called con-
jugation, is mediated by a number of enzymes,9,17,26 and is 
generally not affected by age.9 Anesthesiologists should thus 
be aware of possible age-related effects on phase I reactions, 
leading to reduced metabolism of agents eliminated by the 
hepatic system (eg, aminosteroid NMBAs).9,17
Muscle effects of aging
Loss of skeletal muscle strength is a commonly recog-
nized consequence of aging. Average reported age-related 
decreases in strength are 20%–40% for both men and women 
in both proximal and distal muscles.28,29 Longitudinal studies, 
with some exceptions, have reported somewhat-greater losses 
of strength over time (1%–3% per year) compared with cross-
sectional studies.28,29 Although age-associated decreases 
in strength per unit muscle mass (ie, muscle quality) may 
play a role, the majority of strength loss can be accounted 
for by decreased muscle mass of ~40% between the ages 
of 20 and 60 years29 and nearly 50% between the ages of 
20 and 90 years.30 Age-related loss of muscle mass appears 
to be fairly consistent, occurring at a rate of approximately 
1%–2% per year after 50 years of age.30 This loss is attrib-
uted to a decrease in both the number and size of skeletal 
muscle fibers.29,30
Aging is also associated with decreased muscle blood 
flow and vascular conductance in the elderly.12,31 Vascular 
function changes with aging include impaired endothelial 
function (eg, impaired formation and activation of nitric 
oxide) and altered reactivity of vascular smooth muscle to 
sympathetic activity. Age-related structural and functional 
alterations in the vascular system may explain age-associated 
reductions in muscle blood flow.31 These changes may 
influence the delivery of drugs to the muscle end plate and 
thereby contribute to delayed onset and longer duration of 
action of most NMBAs, as well as a greater risk of residual 
NMB, in the elderly.31
Pharmacology in the elderly
Pharmacodynamic effects of aging
The effect of age on drug sensitivity varies with the drug 
studied and the response measured. Advancing age is 
associated with increased sensitivity to the central nervous 
system effects of benzodiazepines; propofol, which requires 
a 40%–50% lower dose in patients aged .65 years; inha-
lational anesthetic agents; opioids, especially remifentanil; 
and local anesthetics.17,32 In the field of NM pharmacology, 
possible changes in receptor biological features (eg, ligand 
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affinity and kinetics), perhaps occurring simultaneously with 
altered blood flow to muscles,12,17 has been suggested to 
occur in elderly patients.33,34 These changes involve slower 
release of NMBAs from receptors, delayed recovery of 
receptors, and possibly altered receptor expression at the 
NM junction.33,34
Pharmacokinetic effects of aging
Distribution
In general, the volume of distribution of a drug and the 
plasma concentration produced by a given dose are inversely 
related. With increasing age, lean body mass and total body 
water decrease; therefore, hydrophilic drugs have a smaller 
volume of distribution and thus higher plasma concentration 
compared with those of younger individuals. Consequently, 
the effects of hydrophilic drugs will increase. Conversely, 
elderly patients tend to have a higher percentage of body 
fat. As a result, lipophilic drugs will have a higher volume 
of distribution in the elderly, which may lead to more 
extensive redistribution and a longer elimination half-life 
of lipophilic drugs.9,12
The volume of distribution of a drug is also influenced 
by such factors as protein binding (only unbound drug can 
be distributed), pH, molecular size, and solubility. Most 
anesthetic drugs bind to plasma proteins, primarily albumin. 
Therefore, the free fraction and overall free drug concentra-
tion are inversely related to albumin concentration. Increasing 
the percentage of unbound drug increases the amount of drug 
available to produce an effect. Plasma albumin concentration 
tends to decrease with age, and structural protein changes 
occur with age that lead to decreased efficiency of albumin 
binding, to as little as 20% by the age of 70 years.9,12
Metabolism and excretion
The aging process affects drug metabolism in three main 
ways. First, reduced hepatic blood flow delivers the drug 
to the liver at a slower rate. Second, decreased liver mass 
reduces overall hepatic function. Finally, the liver’s intrin-
sic metabolic activity is decreased.9,12,17 The elimination of 
many drugs from the body occurs primarily via renal excre-
tion. The half-life of these drugs increases as renal function 
decreases.9,12,17
Pharmacodynamic and pharmacokinetic 
properties of sugammadex
Sugammadex (previously Org 25969) is a modified 
γ-cyclodextrin with a circular structure containing eight 
adjoining glucose molecules. The diameters of the inner and 
outer rims of unmodified γ-cyclodextrin are approximately 
0.75 and 0.85 nm, respectively. Modifications to the parent 
molecule involve adding side chains to extend the cavity 
to ~1.1 nm and adding negatively charged groups at the end 
of the side chains to enhance binding. Therefore, the drug is 
modified to better accommodate the four hydrophobic ste-
roidal rings of rocuronium (or vecuronium) and to enhance 
electrostatic binding to the positively-charged quaternary 
nitrogen of rocuronium (or vecuronium).35,36
After injection, sugammadex encapsulates and inactivates 
unbound rocuronium (or vecuronium) by forming tight (K
a
 
1.05×107 mol/L; K
d
 ~0.1 mmol/L) water-soluble complexes 
at a 1:1 ratio. In so doing, sugammadex creates a concentra-
tion gradient favoring movement of rocuronium (or vecuro-
nium) from the NM junction into the plasma, which quickly 
reverses rocuronium- (or vecuronium)-induced NMB.35,36
In healthy adult volunteers, renal excretion of unchanged 
drug has been observed as the primary route of elimination 
for sugammadex (Table 2). The majority (.90%) of a dose 
of sugammadex is excreted within 24 hours of administra-
tion. Sugammadex is primarily (96%) excreted in the urine, 
predominantly (95%) as unchanged drug; excretion in the 
feces or expired air is minimal (0.02%).35–37 Sugammadex 
also increases the amount of rocuronium excreted unchanged 
in the urine.35–37 Administration of rocuronium and sugam-
madex 2 or 4 mg/kg (doses recommended for reversal of 
moderate or deep rocuronium-induced NMB in clinical 
practice, respectively) was associated with a two- to threefold 
increase in urinary excretion of unchanged rocuronium in 
the first 24 hours compared with rocuronium plus placebo in 
healthy volunteers (32% or 44% vs 14% of the administered 
dose).36 The effect of sugammadex on urinary excretion of 
rocuronium appears to be dose dependent.36
Physiologic and pharmacologic effects of 
aging on sugammadex
Efficacy and safety
Some case reports and few clinical studies have evaluated 
the efficacy and safety of sugammadex in elderly patients38–49 
(Table 3). McDonagh et al conducted a parallel-group, com-
parative, open-label study evaluating sugammadex 2 mg/kg 
administered for reversal of moderate rocuronium-induced 
NMB in 150 patients undergoing intravenous or inhalational 
general anesthesia. They compared 48 younger adults (aged 
18–64 years), 62 elderly adults (aged 65–74 years), and 
40 old-elderly adults (aged 75 years).45 The geometric 
mean time (95% CI) from sugammadex administration to 
recovery of train-of-four (TOF) ratio to 0.9 increased with 
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age: from 2.3 (2–2.6) minutes for younger adults to 2.6 
(2.3–2.9) minutes for elderly adults and 3.6 (3.1–4.1) minutes 
for old/elderly adults.45 Recovery of TOF ratio to 0.9 was esti-
mated to be 0.7 minutes faster (P=0.022) in younger adults 
compared with patients aged 65 years (younger adult vs 
elderly and old/elderly groups combined: 2.3 [2–2.6] minutes 
vs 2.9 [2.7–3.2] minutes). Sugammadex was well tolerated, 
and no episodes of recurarization occurred.45 Similarly, in a 
study of 17 patients undergoing electroconvulsive therapy 
with propofol anesthesia, Kadoi et al found a significant dif-
ference in time to recovery to a TOF of 0.9 between eight 
young patients (aged #50 years) and nine elderly patients 
(aged 70 years) (403±37 seconds vs 443±36 seconds, 
P,0.05) after 8 mg/kg sugammadex in the presence of 
moderate rocuronium-induced NMB.48
More recently, in a prospective clinical trial, Yazar et al 
investigated the effect of sugammadex 2 mg/kg on duration of 
recovery from moderate rocuronium-induced NMB in elderly 
patients undergoing sevoflurane anesthesia.44 They found that 
the median (range) time from T
2
 to TOF ratio of 0.9 with 
sugammadex was 3.27 (1.41–5.37) minutes in younger 
elderly adults (aged 65–74 years) and 5.5 (2.47–9.54) minutes 
in older elderly patients (aged 75 years) (P,0.001).44
In a comparative, open-label study, Suzuki et al evalu-
ated 4 mg/kg sugammadex, administered for reversal of deep 
rocuronium-induced NMB, in a group of elderly patients 
(aged 70 years) versus younger patients (aged 20–50 years) 
undergoing sevoflurane anesthesia.46 Recovery of TOF ratio 
to 0.9 was significantly slower in the older group than in the 
younger group (mean [SD] 3.6 [0.7] vs 1.3 [0.3] minutes, 
P,0.0001). There were no clinical events attributable 
to recurarization.46 Similarly, Yamamoto et al found that time 
to a TOF ratio of 1 after sugammadex 4 mg/kg was signifi-
cantly longer in patients aged 70 years than in patients aged 
20–60 years (mean SD 177.6 [42.8] vs 119.9 [9.4] seconds, 
P,0.0001).49
The findings of all these studies reflect the role of age-
related physiologic changes, particularly at muscles and 
NM junctions (eg, decreased muscle blood flow), as well as 
age-related effects on the pharmacokinetics and pharmaco-
dynamics of NMBAs, in slowing the reversal of rocuronium-
induced NMB by sugammadex in elderly patients.44–46,48,49 
To better comprehend the magnitude of the delay in reversal 
of rocuronium-induced NMB by sugammadex in elderly 
compared with younger subjects, we performed a meta-
analysis of English-language controlled trials investigating 
this aspect (Table 3). The meta-analysis of selected studies 
found a significant (P=0.0036) mean difference (95% CI) 
of 1.37 (0.45–2.3) minutes between elderly and younger 
subjects in reversal time of rocuronium-induced NMB by 
sugammadex, a delay in the elderly that should be considered 
in clinical practice (Figure 1).
Age-related decreases in total body water and lean 
body mass, with a smaller apparent volume of distribution 
for sugammadex, may predispose the elderly to increased 
plasma concentrations of the drug after intravenous 
administration. However, this does not appear to reduce 
the safety of sugammadex, which is generally well toler-
ated in patients also at higher doses.50 In a randomized 
multicenter, safety assessor-blinded, parallel-group, active-
control Phase III trial investigating the reversal of profound 
NMB by 16 mg/kg sugammadex administered 3 minutes 
Table 2 Pharmacokinetic characteristics, chemical properties, and physical properties of rocuronium and sugammadex
Pharmacological aspects Parameters Rocuroniuma Sugammadexb
Pharmacokinetic Volume of distribution 
(steady state)
14 (13.5–15) Lc 11–14 L
Metabolism location Liver None
Metabolites 17-Desacetyl-rocuronium
16N-desallyl-rocuronium
None
elimination route Biliary and renal Renal
Elimination half-life 1.2 (1.1–1.3) hours 1.8 (1–4) hours
Plasma clearance 259 (245–273) mL/mind 88 (75–138) mL/min
Protein binding 30% 0%
Chemical and physical Molecular weight 609.7 g/mol 2,178 g/mol
water solubility 0.14 mg/L 31,470 mg/L
Octanol–water 
partition coefficient
0.5 at 20°C −12 at 25°C
Log S§ −6.63 −1.84
Log P=I 1.66 0.85
Notes: a,bData obtained from summaries of product characteristics37,75; and personal communication from Merck & Co., Inc., Medical Division (November 2011 to 
August 2017). c,dVolume of distribution (0.203 [0.193–0.214] L/kg)c and plasma clearance (3.7 [3.5–3.9] mL⋅kg/min)d calculated for an adult weighing 70 kg. §Logarithm 
(base 10) of water solubility (S) obtained with ALOGPS program. Hydrophilicity increases as the value of log S increases. I=Logarithm (base 10) of the octanol–water partition 
coefficient (P), defined as the ratio of the compound’s octanol phase:aqueous phase concentrations obtained with ALOGPS 2. It is a measure of molecular hydrophobicity. 
Hydrophobicity increases as the value of log P0 increases.
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after 1.2 mg/kg rocuronium, Lee et al found no recurrence 
of NMB or serious adverse events related to study treat-
ment.51 Moreover, in a randomized, double-blind, crossover, 
placebo-controlled, single-center study investigating 32, 64, 
and 96 mg/kg doses of sugammadex in 13 healthy adults, 
Peeters et al found that sugammadex was well tolerated in 
12 of 13 subjects. When present, adverse events were gener-
ally mild, of limited duration, and more frequent at higher 
doses. The most common adverse event was dysgeusia, 
and there were no serious adverse events. One subject was 
withdrawn from the study after experiencing several adverse 
events following exposure to sugammadex, attributed to 
probable hypersensitivity to the drug.52
Sugammadex-induced hypersensitivity reactions, includ-
ing anaphylaxis, have been reported with an incidence below 
1%,53,54 and as with all drugs, they are of concern, considering 
that elderly patients are particularly vulnerable to adverse 
drug reactions.55 However, no sugammadex-induced hyper-
sensitivity reactions were reported in the studies evaluating its 
efficacy and safety in elderly patients.42–49 Among 15 cases of 
hypersensitivity following sugammadex administration revised 
by Tsur and Kalansky, only one patient was aged .65 years.56 
Miyazaki et al retrospectively investigated the incidence of 
potential sugammadex-induced anaphylaxis at a single center in 
Japan over a period of 3 years. The total number of patients who 
received sugammadex during the study period was 15,479, and 
the incidence of anaphylaxis associated with sugammadex was 
0.039% (95% CI 0.014%–0.084%). None of the six patients 
involved were aged .65 years.54 Therefore, drug-induced 
hypersensitivity reactions are possible, particularly during the 
critical 5-minute period immediately following sugammadex 
administration,56 but the risk of anaphylaxis associated with 
sugammadex seems to be a rare event in the elderly.42–49,54,56
Influence of differential muscle sensitivity to NMBAs 
and anesthetic agents
Other factors have been investigated in an effort to explain 
the delayed reversal time with aging, such as differential 
sensitivity of various muscles to NMBAs and the potential 
role of general anesthetic drugs. Among the typical NM-
monitoring sites used during clinical anesthesia, the orbicu-
laris oculi and adductor pollicis muscles are described as 
being sensitive to NMBAs. Maximum blockade is more 
profound, and the duration of action is longer at these muscles 
than at the more resistant muscles, such as the corrugator 
supercilii, laryngeal adductors, and diaphragm.57–60 Sugam-
madex, administered to reverse a rocuronium-induced NMB, 
showed different reversal profiles in muscles with different 
sensitivities to NMBAs.49 Yamamoto et al found that reversal 
time observed at the adductor pollicis was significantly longer 
in patients aged 70 years than in patients aged 20–60 years 
(P,0.0001), but there was no difference according to age 
at the corrugator supercilii.49 The explanation for the latter 
finding is unclear, but may reflect preservation of functional 
muscle activity, blood flow, or both at the corrugator super-
cilii with advanced age.49
Propofol and inhalational anesthetics, such as sevoflurane 
or desflurane, are widely used for maintenance of anesthesia. 
In contrast to propofol, inhalational anesthetics enhance 
the effects of certain NMBAs, including rocuronium. They 
increase the intensity of NMB,61 and in some cases prolong 
the duration of action of rocuronium and time to recovery.61,62 
However, sugammadex has been shown to be equally effec-
tive for reversing moderate and deep rocuronium-induced 
NMB during sevoflurane or propofol anesthesia.63,64 This sug-
gests that sevoflurane does not pharmacodynamically inhibit 
chemical binding between rocuronium and sugammadex.64,65 
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Figure 1 Forest plot of meta-analysis of data from controlled studies of sugammadex for reversal of rocuronium-induced NMB in elderly compared with younger subjects.
Notes: Inclusion and exclusion criteria, search strategy, and methodology described elsewhere15 and in Table 3. To analyze reversal times (expressed in minutes), means and 
SDs were compared by mean difference (MD) and 95% CI for continuous-outcome data.15 Meta-analysis was performed using both random- and fixed-effect models. The 
random-effect model was computed with inverse-variance weighting using the DerSimonian–Laird method to account for heterogeneity. Heterogeneity across studies was 
tested using the I2 statistic.15 I2.50% was considered substantial.15 Experimental, sugammadex at 245 or 4 mg/kg46,49 administered for reversal of moderate or deep rocuronium-
induced NMB, respectively, in the elderly; controls, sugammadex at 2 or 4 mg/kg administered for reversal of moderate or deep rocuronium-induced NMB, respectively, in 
younger subjects. Meta-analysis demonstrated a significant MD (95% CI) of 1.37 (0.45–2.3) (P=0.0036) in reversal time of rocuronium-induced NMB by sugammadex, delayed 
in elderly compared with younger subjects.
Abbreviation: NMB, neuromuscular blockade.
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Nevertheless, Dwyer and Howe showed that perfusion of 
forearm muscle and skin is maintained in patients aged 
18–34 years, but not in patients aged 60–79 years, dur-
ing anesthesia when receiving isoflurane at 0.8%–1.2% 
combined with nitrous oxide at 66%.66 This suggests that 
inhalational anesthesia may have some influence on slowing 
the recovery from NMB by sugammadex through further 
reducing cardiac output and muscle blood flow, both of 
which are already decreased with age. Changes in blood flow 
to peripheral tissues produced by volatile anesthetics may 
thereby contribute to age-related variations in recovery from 
rocuronium-induced NMB with sugammadex.46
Dose considerations
Based on the aforementioned findings and the physiologic 
changes that occur with aging, older patients may be 
expected to require a higher dose of sugammadex to achieve 
adequate recovery from NMB within a short time.67 In a 
study comparing 22 young (aged 20–40 years) and 22 elderly 
(aged 70 years) adults administered 4 mg/kg sugamma-
dex to revert deep rocuronium-induced NMB (one to two 
posttetanic counts), Shin et al reported that the ED
95
 (95% 
CI) of sugammadex for adequate recovery within 2 minutes 
was 5.4 (4.9–5.5) mg/kg in elderly adults and 4.4 (3.9–4.5) 
mg/kg in young adults.67 Dose adjustments of sugammadex 
should thus be considered when rapid recovery from deep 
NMB is required in elderly adults.67
Respiratory and cardiovascular dysfunction
Aging affects respiratory and cardiovascular system and the 
elderly may present respiratory and cardiovascular diseases. 
However, there are no limitations on the use of sugam-
madex in the presence of age-related respiratory and/or 
cardiovascular dysfunction. In a randomized, multicenter, 
parallel-group, comparative, safety assessor-blinded study 
involving 77 patients with pulmonary disease, sugamma-
dex was shown to be safe and effective for the reversal of 
rocuronium-induced NMB.68 Compared to neostigmine, 
sugammadex has been associated with significantly less risk 
of postoperative desaturation (RR 0.23, 95% CI 0.06–0.83) 
and need for transitory oxygen supplementation (RR 0.24, 
95% CI 0.09–0.66) and (not significant) less risk of lar-
yngospasm (RR 0.34, 95% CI 0.07–1.65) and increased 
upper-airway secretion (RR 0.37, 95% CI 0.09–1.59).69 
Compared to neostigmine, sugammadex has been associated 
with a not significant greater risk of cough (RR 1.42, 95% CI 
0.42–4.81).69 Restoration of cough and swallowing reflexes 
is key to preventing pulmonary aspiration after anesthesia 
in the elderly.70 However, it is possible that the straining that 
occurs during coughing can be responsible for provoking 
reflux events and pulmonary aspiration.71 Awareness on this 
aspect is then important.70,71
In a randomized, safety assessor-blinded, placebo- 
controlled trial, Dahl et al found that sugammadex can be 
given safely and effectively for reversal of rocuronium-
induced NMB in patients with cardiovascular disease 
undergoing noncardiac surgery.72 Kizilay et al suggested 
that sugammadex might be preferable, as it provides more 
hemodynamic stability compared to neostigmine-atropine 
combination in cardiac patients (aged 18–75 years) under-
going noncardiac surgery.73 A significantly lower risk of 
bradycardia (RR 0.16, 95% CI 0.07–0.34) and (not signifi-
cant) lower risk of tachycardia (RR 0.44, 95% CI 0.09–2.22) 
and supraventricular extrasystoles (RR 0.32, 95% CI 
0.03–3.05) has been reported.69 Furthermore, sugammadex 
alone or in combination with rocuronium or vecuronium is 
not associated with QTc prolongation.74
Liver and kidney dysfunction
Unlike aminosteroid NMBAs,12,75 sugammadex is not 
metabolized by the liver, and age-related changes in liver 
function should not affect the drug’s pharmacokinetic 
profile.37 By contrast, as sugammadex is primarily excreted 
in an unchanged form via urine within 24 hours at usual 
clinical doses (Table 2),37 its potential role in kidney func-
tion may be suspected, and alteration of the drug’s pharma-
cokinetic profile may be expected with changes in kidney 
function.76–78
On the first aspect, considering that both acetylcholin-
esterase inhibitors (~50%) and sugammadex (95%) are 
excreted unchanged by the kidneys, Isik et al investigated 
the effects of neostigmine (25 patients) and sugammadex 
(25 patients) on kidney function by means of sensitive 
biomarkers (eg, cystatin C) after a surgical procedure under 
desflurane/opioid anesthesia. They found that both drugs may 
affect kidney function, but sugammadex had more tolerable 
effects than neostigmine.76
Age-associated loss of kidney function may affect the 
elimination of sugammadex. In patients with a creatinine 
clearance ,30 mL/min, sugammadex clearance is reduced 
by 17-fold and elimination half-life by 15-fold compared 
with patients without renal impairment.77 In a Phase III trial, 
Staals et al reported pharmacokinetic data obtained from 
26 patients who received rocuronium at 0.6 mg/kg followed 
by a single dose of sugammadex at 2.0 mg/kg at reappearance 
of two twitches during TOF monitoring. Mean total plasma 
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clearance of sugammadex was 5.5 mL/min in patients with 
impaired renal function (creatinine clearance ,30 mL/min) 
and 95.2 mL/min in normal controls (P,0.05). Rocuronium 
clearance was also reduced: 41.8 mL/min in patients with 
renal impairment and 167 mL/min in controls (P,0.05). 
Median percentages of administered sugammadex and 
rocuronium excreted in the urine over 72 hours were 29% 
and 4%, respectively, in patients with renal impairment, 
in contrast to 73% and 42%, respectively, over 24 hours 
in controls.78
By contrast, the efficacy of sugammadex is not altered 
by impaired renal function. After administration of 2 mg/kg 
sugammadex to reverse moderate rocuronium-induced NMB, 
the mean (SD) time to recovery of TOF ratio to 0.9 was 
2 (0.72) minutes in 15 patients with impaired renal function 
and 1.65 (0.63) minutes in 15 normal controls (P.0.05). 
Furthermore, no block recurrence was observed.75 Recently, 
Min et al published their results of an open-label, two-part, 
Phase I study of 18 adults with moderate (creatinine clearance 
30–50 mL/min) or severe (creatinine clearance ,30 mL/min) 
renal impairment and healthy controls.79 After 4 mg/kg 
sugammadex, pharmacokinetic data showed that the mean 
sugammadex exposure (area under the plasma concentration 
vs time curve) in subjects with moderate and severe renal 
impairment was 2.42 and 5.42 times, respectively, that of 
healthy controls. Clearance decreased and apparent terminal 
half-life was prolonged with increasing renal dysfunction. 
There were no serious adverse events or episodes of recu-
rarization. Therefore, dose adjustment of sugammadex is 
not required in patients with moderate renal impairment.66 
However, current evidence evaluating safety is insufficient to 
support the use of sugammadex in patients with a creatinine 
clearance below 30 mL/min.77–79
Conclusion
In conclusion, aging is associated with certain changes in 
the pharmacokinetics of sugammadex when used in elderly 
patients. In patients aged .65 years, time to recovery from 
rocuronium-induced NMB after sugammadex administration 
is prolonged on average by 1–2 minutes compared to younger 
patients. However, this delayed reversal of rocuronium-
induced NMB is not associated with reduced efficacy of the 
drug or an increased risk of adverse effects in the elderly. 
Therefore, special dose recommendations have not been 
issued for older patients. However, if it is necessary to 
achieve adequate recovery of rocuronium-induced NMB in 
a short period, then a greater dose of sugammadex may be 
considered.
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